In a patient with stage III NSCLC who was treated with neoadjuvant systemic therapy and had a PR, would you deliver RT to all sites of initially involved disease, or only residual sites of disease?

I struggle with this one quite often. The data would suggest that you need to treat all initial sites, but of course, that's not the purpose of those studies (defining what sites, dose to sites, etc) and there's almost assuredly something going on with that aspect of the therapy. The other way to th...